Evotec SE

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 10:05:19 13/03/2026 pm IST			5-day change	1st Jan Change
4.175 ^EUR	-3.02%		-22.71%	-23.39%

12/03	EVOTEC : Deutsche Bank reaffirms its Neutral rating	ZD
11/03	EVOTEC : Deutsche Bank is Neutral	ZD

Warburg Research lowers target for Evotec to €12.10 – 'Buy'

Published on 04/23/2025 at 03:04 pm IST

dpa-AFX - Translated by Marketscreener - See original

EVOTEC SE

-3.02%

HAMBURG (dpa-AFX Broker) - The research firm Warburg Research has lowered its price target for Evotec from €14 to €12.10, but has maintained its "buy" rating. The Biologics segment – development and production services for antibodies, next-generation biologics and biosimilar products – performed surprisingly well, wrote analyst Christian Ehmann in his review of the financial results published on Wednesday. However, the outlook for 2025 was disappointing, especially with regard to margins.

Publication of the original study: April 23, 2025 / 8:15 a.m. / CEST

Initial distribution of the original study: April 23, 2025 / time not specified in study / CEST

-----------------------

dpa-AFX Broker – trader news from dpa-AFX

-----------------------

Latest news about Evotec SE

12/03	EVOTEC : Deutsche Bank reaffirms its Neutral rating	ZD
11/03	EVOTEC : Deutsche Bank is Neutral	ZD
11/03	Evotec SE - Special Call
10/03	Frankfurt Stock Market Close: Dax recovers as oil prices retreat	DP
10/03	EARNINGS AND TRADING: Ondine trial on track; Ensilica's contract wins	AN
10/03	Solvonis Selects Lead Compound for Post-traumatic Stress Disorder Discovery Program	MT
10/03	Evotec SE Provides Earnings Guidance for the Full-Year 2026	CI
10/03	Evotec SE Revises Earnings Guidance for the Full Year 2025	CI
10/03	Evotec Accelerates Restructuring: Job Cuts and Site Closures Trigger Stock Plunge	DP
10/03	EVOTEC : RBC reiterates its Buy rating	ZD
10/03	Evotec Shares Plunge as Key Chart Support Fails	DP
10/03	Frankfurt Stock Exchange Opening: Dax Gains Momentum on Recovery Path	DP
10/03	Solvonis Therapeutics plc Announces Selection of SVN-114 as Lead Candidate from its Proprietary SVN-SDN-14 Discovery Programme	CI
10/03	Evotec introduces new phased 2026-2030 mid-term framework, aligned with Transformation Roadmap	RE
24/02	Centauri Therapeutics Limited announced that it has received £30 million in funding from a group of investors	CI

Chart Evotec SE

Duration

Period

EVT: Dynamic Chart

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, womenâ€™s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Employees

4,788

Sector

Biotechnology & Medical Research

Calendar

08/04 - Earnings release - Q4 2025

More about the company